1 / 7

NATURFIERA-CATANIA- 8GIU.2013 Prof . Calogero Rinzivillo Farmacista-medico specialista 3394201756-3293178092-0953782378

Oncologia:novità su onco-metabolismi e connesse terapie integrate fito bio - enzinutri -dinamiche . PROBIOTICI:usi innovativi multiattivi e connesse terapie in oncologia, gastroenteroL ., metab ., antietà,ecc . NATURFIERA-CATANIA- 8GIU.2013 Prof . Calogero Rinzivillo

cili
Télécharger la présentation

NATURFIERA-CATANIA- 8GIU.2013 Prof . Calogero Rinzivillo Farmacista-medico specialista 3394201756-3293178092-0953782378

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Oncologia:novità su onco-metabolismi e connesseterapie integrate fitobio-enzinutri-dinamiche.PROBIOTICI:usi innovativi multiattivie connesse terapiein oncologia,gastroenteroL.,metab.,antietà,ecc. NATURFIERA-CATANIA-8GIU.2013 Prof. Calogero Rinzivillo Farmacista-medico specialista 3394201756-3293178092-0953782378 095435565-rinzivil@unict.itt nucli@policlinico.unict.it VICEPRES.AMIFIT-ASS.IT.MED.INTEGR.FITOT. - Az. Osped.Universit.Policlinico Vittorio Emanuele-Edif.4-via S. Sofia- Catania

  2. Presidente Dr.a Patrizia Tosto 14 Apr.2013-Paradiso Etna-1°CongressoNaz. A.M.I.Fit.Ass.Italiana Medicina Integrata e Fitoterapia-

  3. Prof. C. Rinzivillo (Passione,studio NutriFitoInt.e ter.nat.integr.daì76 =oltre 35anni) (Cent. m.: Erythraea centaurium, fosfat. col.) Lauree:Farmacia, Medic.e Special.max voti,lode e proposta premi Premio Fondazione Internazionale “G.GALILEI” (Ginevra) e Premio Lions per ricerca medica e nutrizione; Relazione premiata Congresso Nazionale ADI-Giardini-Ass.Diet.Nutr.Clin.(uso integratori alimentari e cofattori e proteine in operati oncologici stomizzati, preventive o per deficit nutrizionali) Oltre 150 pubblicazioni scientifiche su temi di gastroenterologia, nutrizione clinica, supporto in chirurgia, gastroent.,oncologia, malattie metaboliche,medicina benessere e antinvecch.,fito-nutri-int. Finanz.vari progetti Ateneo\Dip.:terapie mediche integrate,in partic.paz.Chir.,Oncol.,App.dig.,Metab già o attuale Socio varie Soc.Medico-Scientifiche, fra cui:° New York Academy of Sciences, ° ADI-Ass. Ital.Diet.Nutriz.Clinica, ° SINPE Soc.Ital. Nutrizione Parent. Enterale, ° AIOT- Ass.It.OmeoTossic.-Medic.Biologica- MEDIBIO; °MASTER Annuale e socio AMIDEAV Ass.Medica Ital.Elettr.Agopunt.; ecc. Resp.1°Prog.Ricerca Finaliz.Sanit.Reg.”NUTRI-FITOINTEGRAT. IN PAZ. CHIRURG.,ONCOL.,DISMETAB.”

  4. ONCOLOGIA • principio attivo antiinfiammat.dellacurcuma,tradizionale per secoli AY,MTCinese. • capacità curcumina causare apoptosi solo negli ONCOCITI mentre miglioravan funzioni ‘normali’ di cellule normali-ANDERSON CANCER CENTER TEXAS 2011 • Ciò è confermato da Ospedale Zheijian-Cina, in particolare apoptosi in cellule del BC cancro mammario TNBC=triplo negativo (recettori E,P, EGrF), più difficile da curare dei BC recett.+. • Tale effetto è potenziato se si usano cibi e integratori ricchi di flavanoli, in particolare epigallocatechina gallato (EGCG) del tè verde, effetti ottimi antiox e anti-neoangiogenetico antiflog.se  usato con diferuloilmetano da curcumina. • SITI WWW. : -greenmedinfo.com/substance/curcumin; • naturalnews.com/037879_curcumin_cancer_cells_turmeric.html • ncbi.nlm.nih.gov/pubmed/23740392 (Singh&Misra.Interdisc.Sc.2013 June) (diferuloylmethane) and itsnaturallyanalogsdemethoxy, bisdemethoxy and cyclocurcumin, present in rhizomes of curcuma speciesturmeric, inhibit the proliferation of a wide variety of tumorcells. AA.shows thatCurcumin targets (EpiG.n)nuclearprotein HPV16E6,major proteinactivelydevelopingoral&cervical K • Curr Cancer Drug Targets,2013 Apr 17. [ahead of print], ClinicalOncology, Queen Elizabeth Hospital- HONG KONG-By Wang Y e C.: Genetic And Epigenetic Studies For Determining Molecular Targets Of Natural Product Anticancer Agents->EGCG, curcumin, genistein, sulforaphane and resveratrolhaveanticancerpropertiesthrough the mechanisms of alteringepigeneticprocesses[including DNA methylation, histonemodification, chromatinremodeling, microRNA (miRNA) regulation] and targetingcancerstemcells(CSCs)

  5. ONCOLOGIA • Chem.Commun.(Cambridge Press) 2013 Jul-Cl.studyc3cc41858h. Ahead of PRINT Chemicalproteomics-drivendiscovery of oleocanthalas an Hsp90 inhibitor. by Margarucci L. e C.-Dipart.FarmaciaUniv. Salerno- Hsp90 is a key target in cancer therapy. Oleocanthal, olive oil active compound, is its inhibitor. • NutrMetabCardiovasc Dis.2013 Feb 25.(ahead of print] Mediterraneandiet and non enzymaticantioxidantcapacity in the PREDIMED study: Evidence for a mechanism of antioxidanttuning. By Zamora R.e C. 1-year of correct MED diet increases plasma TAC:TOTAL ANTIOXIDANT Capacity level. • Colloids Surf B Biointerfaces.2013 Jun.Ahead of print.ElsevierScient.Intern.Publish.Spontaneous ultra fast synthesis of goldnanoparticlesusingPunica granatumfor cancertargeteddrugdelivery.-ByGaneshkumarM.&C.-India-CSIRCounc.Scient.Ind.Res. Free 5-Fu,vs 5Fu@Pun.NanoPs was investigated against MCF-7 cells (breast cancer)and we observed that amount of 5Fluoruracil(CH)required to achieve 50%of growth-inhibition was much lower VS free 5Fu. • ->cytochrome P450 enzyme, CYP1B1, is a target in prostate cancer.Compoundsinhibiting CYP1B1 activity are contemplated to exertbeneficialeffectsatthreestages of prostate cancerdevelopment, thatis, initiation, progression, and development of drugresistance. Pomegr.ellagitannins/intest.microbialmetabolites/: Urolithin A was the most potent uncompetitive inhibitor of CYP1B1,with a dual mode mechanism by decreasing CYP1B1 metabolic activity and expression (epigenetics).Punicalins and punicalagins exhibited potent CYP1A1 inhibition, also-J Agric Food Chem.2009 Nov<-Missisippi Un.->AND J Agric Food Chem.2010 Feb: Colon cancer chemopreventive activities of pomegranate ellagitannins and urolithins

  6. ONCOLOGIA • J Mol Endocrinol.2013 May 29. [Ahead of print] Antioxidant and anti-growth action of peracetylatedoleuropein in thyroid cancer BulottaS.e C. phenolic components oleuropein and its derivatives.OLE inhibited significantly proliferation This effect was paralleled by a reduction of basal phospho-Akt and phospho-ERK levels and H2O2induced ROS levels. A stronger effect by Ac-OLE in inhibiting cell growth and as antioxidant(vitro). • Cytotechnology.-2009 Jan;59(1) Anti-proliferative and apoptotic effects of oleuropein and hydroxytyrosol on human breast cancer-University of Tsukuba-Japan-by Han J. & c.- • Effects of anthocyanidins (cyanidin, delphinidin, malvidin, peonidin, petunidin, pelargonidin) on the arylhydrocarbonreceptor (AhR)-CYP1A1 signalingpathway in human hepatic&intest.Kcells. Pelargonidin can bind to and activate the AhR and AhR-dependent gene expression, and pelargonidin and delphinidin inhibit the CYP1A1 catalytic activity -UNIV. BARCELLONA (Zamora R. e C.) staapprofondendo DIETA MED.eeffettisuoiprincipiattivigiàdimostrati in vivo e vitro come antiox e antitum.disupporto PRINCIPI (MALVIDINA ecc.): vedi Br. J. Nutrition 2012 e altreriviste s

  7. ONCOLOGIA • PASTEUR EFFECT • WARBURG EFFECT • REVERSE WARBURG EFFECT (LISANTI) • CRABTREE EFFECT NUTRIENTI ENZIMATIZZATI BIODINAMICI OTTIMIZZATI

More Related